An equity cure is a contractual mechanism that can allow qualifying shareholder funds to be injected so a failed financial covenant is treated as cured under the loan terms. The right is not automatic in every facility, and the drafting determines whether cure money affects EBITDA, net debt or another part of the covenant calculation.
Understanding equity cures for financial covenants without the jargon
An equity cure is a contractual mechanism that can allow qualifying shareholder funds to be injected so a failed financial covenant is treated as cured under the loan terms. Treasury should therefore test the exact wording or processor response before assuming the same treatment applies to every transaction.
The right is not automatic in every facility, and the drafting determines whether cure money affects EBITDA, net debt or another part of the covenant calculation. That makes traceability essential: the bank record, internal approval and accounting entry should all point back to the same commercial event.
What happens operationally with equity cures for financial covenants
Agreements can restrict the number of cures, consecutive use, maximum amount, timing and whether the cash must be retained or used to prepay debt. A simple written control around this point can prevent a later cash, reconciliation or customer-service problem that is much harder to unwind.
The mechanism can buy time for a viable business, but repeated shareholder injections can indicate that the operating plan or capital structure needs a more durable change. The practical objective is not more paperwork; it is to know what must happen next and who has authority to change the planned outcome.
Records and approvals that determine the result
Treasury should preserve the original covenant calculation, the proposed cure calculation, board approval, lender notice and evidence that qualifying funds were received.
A shareholder payment that arrives too late, uses the wrong instrument or exceeds the amount allowed to count may fail to cure the covenant despite increasing cash.
The main practical risks
Covenant forecasts should be prepared early enough for shareholders to decide whether they will provide funds before the contractual cure deadline.
A cure that fixes the ratio but leaves the company unable to meet payroll, suppliers or interest does not solve the underlying liquidity problem.
Worked example: a realistic business case
A leverage covenant allows an eligible equity contribution to increase covenant EBITDA for the test. A £1 million shareholder injection may change the ratio only if the agreement expressly permits that treatment and every timing and form condition is satisfied.
Use the example as a method, not a universal rule. The article-specific control point is this: Agreements can restrict the number of cures, consecutive use, maximum amount, timing and whether the cash must be retained or used to prepay debt. The business should reproduce the numbers and timing from its own contract, bank service or processor record before acting.
Monitoring equity cures for financial covenants after implementation
Implementation check: Treasury should preserve the original covenant calculation, the proposed cure calculation, board approval, lender notice and evidence that qualifying funds were received. The operating owner should convert that requirement into a named approval, a dated record and a reconciliation step so the intended treatment can be reproduced later.
Monitoring check: Covenant forecasts should be prepared early enough for shareholders to decide whether they will provide funds before the contractual cure deadline. Management reporting should show whether this control is working, including unresolved exceptions and material changes rather than only completed transaction volume.
Escalation check: A cure that fixes the ratio but leaves the company unable to meet payroll, suppliers or interest does not solve the underlying liquidity problem. If the assumption behind that point changes after approval, treasury should stop and reassess the transaction before cash, credit exposure or customer outcome becomes irreversible.
Decision check: The mechanism can buy time for a viable business, but repeated shareholder injections can indicate that the operating plan or capital structure needs a more durable change. The commercial choice should be made with that trade-off visible, then recorded together with the reason management accepted the remaining risk.
Editorial Verdict
BanksGB’s view starts with the underlying rule: An equity cure is a contractual mechanism that can allow qualifying shareholder funds to be injected so a failed financial covenant is treated as cured under the loan terms. For equity cures for financial covenants, the business should be able to show how that rule connects to the amount, timing, legal entity and financial outcome of the transaction rather than relying on the product label.
The second test is operational: A shareholder payment that arrives too late, uses the wrong instrument or exceeds the amount allowed to count may fail to cure the covenant despite increasing cash. A strong equity cures for financial covenants process makes that failure mode visible early, preserves the evidence used for the decision and gives management a realistic escalation route before the position becomes expensive to unwind.
Sources
- Practical Law, Loan Agreement Equity Cure Clause: https://content.next.westlaw.com/practical-law/document/Id4b88dd1012211e798dc8b09b4f043e0/Loan-Agreement-Equity-Cure-Clause?contextData=%28sc.Default%29&transitionType=Default&viewType=FullText
- Association of Corporate Treasurers, Loan documentation resources: https://www.treasurers.org/loandocumentation